Literature DB >> 11239921

Perinatal opioids reduce striatal nerve growth factor content in rat striatum.

V W Wu1, Q Mo, T Yabe, J P Schwartz, S E Robinson.   

Abstract

Both human and animal models indicate that perinatal methadone exposure produces a variety of short- and long-term neurobehavioral consequences, including disruption of normal development of striatal cholinergic neurons. Despite this, methadone maintenance is a standard method of managing pregnant heroin addicts, and the opioid receptor partial agonist buprenorphine is under evaluation for the same use. We now report that perinatal administration of either methadone or buprenorphine reduces the content of the neurotrophic factor nerve growth factor (NGF) in rat striatum, which may explain the behavioral deficits observed. Furthermore, although NGF content is reduced, there are no corresponding reductions in striatal NGF mRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239921     DOI: 10.1016/s0014-2999(01)00807-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

2.  White Matter Injury and Structural Anomalies in Infants with Prenatal Opioid Exposure.

Authors:  S L Merhar; N A Parikh; A Braimah; B B Poindexter; J Tkach; B Kline-Fath
Journal:  AJNR Am J Neuroradiol       Date:  2019-10-17       Impact factor: 3.825

Review 3.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

Review 5.  Modeling prenatal opioid exposure in animals: Current findings and future directions.

Authors:  Elizabeth M Byrnes; Fair M Vassoler
Journal:  Front Neuroendocrinol       Date:  2017-09-28       Impact factor: 8.606

6.  Opioids affect the fetal brain: reframing the detoxification debate.

Authors:  Steve N Caritis; Ashok Panigrahy
Journal:  Am J Obstet Gynecol       Date:  2019-07-16       Impact factor: 8.661

Review 7.  Neuroimaging in infants with prenatal opioid exposure: Current evidence, recent developments and targets for future research.

Authors:  Rupa Radhakrishnan; Gregory Grecco; Kellen Stolze; Brady Atwood; Samuel G Jennings; Izlin Z Lien; Andrew J Saykin; Senthilkumar Sadhasivam
Journal:  J Neuroradiol       Date:  2020-10-13       Impact factor: 3.447

8.  Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment.

Authors:  O Levran; E Peles; S Hamon; M Randesi; C Zhao; B Zhang; M Adelson; M J Kreek
Journal:  Pharmacogenomics J       Date:  2011-03-01       Impact factor: 3.550

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 10.  Neonatal opioid exposure: public health crisis and novel neuroinflammatory disease.

Authors:  Vikram Vasan; Yuma Kitase; Jessie C Newville; Shenandoah Robinson; Gwendolyn Gerner; V Joanna Burton; Lauren L Jantzie
Journal:  Neural Regen Res       Date:  2021-03       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.